Can severity be predicted by treatment variables in rheumatoid arthritis administrative data bases?

Journal of Rheumatology

Volumn 33, Issue 10, 2006, Pages 1952-1956

  Wolfe, Frederick ^a,d   Michaud, Kaleb ^b   Simon, Teresa ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

Author keywords

Biologics; Disease modifying antirheumatic drugs; Rheumatoid arthritis; Severity; Treatment

Indexed keywords

ADALIMUMAB; AURANOFIN; AZATHIOPRINE; BIOLOGICAL FACTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ACCURACY; ADMINISTRATIVE DATA BASE; ADULT; AGED; ARTICLE; DATA BASE; DISEASE SEVERITY; DRUG EFFECT; FATIGUE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ACTIVITY SCALE; PATIENT GLOBAL SEVERITY; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

AGED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGRESSION ANALYSIS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 33750017051     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Res Ther 2005;7:R333-42.
2. Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 2000;9:549-56.
3. Pigeot I, Ahrens W. Databases as a source for monitoring systems of drug safety [German]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004;47:513-7.
4. Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 2002;11:477-86.
5. Strom BL, Schinnar R, Bilker WB, Feldman H, Farrar JT, Carson JL. Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen. Arch Intern Med 1997;157:2626-31.
6. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135-41.
7. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997;19:346-66.
8. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
9. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004;164:2472-6.
10. Walley T, Duggan AK, Haycox AR, Niziol CJ. Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. J R Soc Med 2003;96:525-31.
11. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10.
12. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology Oxford 2000;39:975-81.
13. Shipton D, Glazier RH, Guan J, Badley EM. Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population. Med Care 2004;42:907-13.
14. Powell KE, Diseker RA III, Presley RJ, et al. Administrative data as a tool for arthritis surveillance: estimating prevalence and utilization of services. J Public Health Manag Pract 2003;9:291-8.
15. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalisation for congestive heart failure in rheumatoid arthritis. Rheumatology Oxford 2005;44:677-80.
16. Askling J, Fored CM, Baecklund E, et al. Hematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20.
17. Askling J, Fored M, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and following treatment with TNF-antagonists. Ann Rheum Dis 2005;64:1421-6. Epub 2005 April 13
18. Aho K, Kaipiainen-Seppanen O, Heliovaara M, Klaukka T. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum 1998;27:325-34.
19. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies and clinical trials: The Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005;32:2410-5.
20. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6396 persons with rheumatoid arthritis. J Rheumatol 2005;32:1875-83.
21. Wolfe F, Michaud K. A brief introduction to the National Data Bank for Rheumatic Diseases. Clin Exp Rheumatol 2005;23:S168-71.
22. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11.
23. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18.572 patients. Arthritis Rheum 2004;50:1740-51.
24. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
25. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
26. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
27. Meenan RF, Gertman PM, Mason JH, Dunaif R. The Arthritis Impact Measurement Scales. Arthritis Rheum 1982;25:1048-53.
28. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey. Med Care 1988;26:724-35.